Molecular Docking for Chalcone Analogue Compounds as Inhibitor for Lung Cancer A549

Authors

  • Neni Frimayanti Sekolah Tinggi Ilmu Farmasi Riau
  • Meiriza Djohari Sekolah Tinggi Ilmu Farmasi Riau ,
  • Alifah Nurul Khusnah Sekolah Tinggi Ilmu Farmasi Riau ,

DOI:

https://doi.org/10.35814/jifi.v19i1.765

Keywords:

Chalcone, gefi tinib, molecular docking, protein 4HFZ, lung cancer cell A549

Abstract

Chalcones are compounds derived from nature, it is show the anticancer activity. The aim of this
study is to determine the binding free energy (affi nity) and interaction of chalcone derivatives as inhibitors for A549 lung cancer cells using 4HFZ protein as receptors. This study used 10 chalcone derivatives which were selected with three lowest IC50 values, fi ve medium IC50 values and two with higher IC50 values (i.e. more than 100 μg/mL) and 4HFZ protein was used as receptor. The structure of the chalcone derivative is transformed in 3D structure, then the docking process of chalcone compounds with amino acids on the MDM2 receptor (4HFZ) is carried out. The simulation results shown that data in the form of binding free energy value (kcal / mol) shown the stability of ligand interaction of chalcone compounds on amino acids on MDM2 receptors. The docking results shown that, compound 2 is able to bind strongly with MDM2 receptor (4HFZ) and it is also stable because it has a low binding-free energy value of -7.2 kcal / mol, with a RMSD value of 0,000. Construction of some hydrogen bonds is the same as active receptor (gefi tinib), they are Leu54 on the NH2.

References

Downloads

Published

2021-04-30

Issue

Vol. 19 No. 1 (2021): JIFI

Section

Articles

License

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.